Algorae Pharmaceuticals

Algorae Pharmaceuticals (#ASX: #1AI) is a pharmaceutical R&D company developing novel treatments for debilitating conditions including #Dementia

[Algorae Pharmaceuticals @algoraepharma]

#1AI expands its AI drug discovery pipeline.

Algorae has used its AOS2 platform to assess more than 9 million potential drug combinations across 18 anchor drugs, broadening its pool of AI-predicted therapeutic opportunities.

Early filtering has identified:
• 478,000+ synergy predictions meeting preliminary thresholds
• 6,000+ combinations showing predicted synergy across multiple cell lines

Algorae will now work through the data to shortlist candidates for further evaluation and potential preclinical validation.

Read the announcement: https://t.co/IaFt0fH2Pr

#ASX #Biotech #AI #DrugDiscovery

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: #1AI) is continuing to strengthen its ANZ commercialisation strategy.

In the webinar, Executive Chairman David Hainsworth discusses the Company’s growing partner pipeline, with four commercial agreements secured in nine months across its generic and specialty medicines strategy.

🎥 Watch the replay: https://t.co/4XDpcb8TBb

#ASX #1AI #Pharmaceuticals #InvestorRelations

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: #1AI) continues to build momentum across both its commercial and R&D divisions.

Near-term catalysts include TGA registration progress, first revenue expected in 2026 with a pathway to scale, and continued expansion of its pharma partner pipeline.

On the R&D side, development of AlgoraeOS is advancing (Version 3 underway), with upcoming study results and potential new AI-focused partnerships on the horizon.

🎥 Watch the webinar replay: https://t.co/6ThSDEi4a8
👉Visit: https://t.co/DYgOhcz2aN
🎵: https://t.co/PXt2oWF7jG

#ASX #1AI #Pharmaceuticals #InvestorRelations

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: #1AI) is positioning to capture a significant opportunity in the mature, high-value ANZ pharmaceutical market.

In the latest webinar, Executive Chairman David Hainsworth discusses the Company’s growing generic and specialty medicines pipeline, world-class supply partners, and AlgoraeOS — its AI platform that is becoming a genuine asset in its own right.

🎥 Watch the replay: https://t.co/GNZqJGcuGe

#ASX #1AI #Pharmaceuticals #InvestorRelations

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: #1AI) has been featured as a Speculative Buy in The Bull’s latest Buy Recommendations.

The feature notes recent independent validation of AlgoraeOS, the Company’s emerging commercial strategy and a strengthened balance sheet following its recent capital raise.

🗞️Read more: https://t.co/nqrIyMqZjd

#ASX #1AI #Pharmaceuticals #Biotech

[Algorae Pharmaceuticals @algoraepharma]

🎵 https://t.co/FMyO2E5UyL

[Algorae Pharmaceuticals @algoraepharma]

The replay of Algorae Pharmaceuticals’ (ASX: #1AI) investor webinar is now available.

Executive Chairman David Hainsworth outlines Algorae’s progress in building a capital-light pathway to pharmaceutical commercialisation, supported by recent agreements with leading global manufacturers, an expanding product pipeline and progress through the TGA approval pathway.

The session also covers the Company’s pathway to first revenue in 2026 and the longer-term opportunity through AlgoraeOS, its AI-enabled drug discovery platform.

🎥 Watch the replay: https://t.co/AReF5DPdjd
👉🏼 Get in touch for more on 1AI: https://t.co/h4Vc4tChN4

#ASX #1AI #Pharmaceuticals #AlgoraeOS

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: 1AI) reported progress across both parts of its business during the March quarter.

Key highlights:
•Cash increased to ~$5.47m
•Cadila agreement executed, with TGA planning underway
•Zydus agreement added post-quarter for 10 products across ANZ
•Second Peter Mac validation program commenced
•Commercial team strengthened to support AlgoraeRx

A solid quarter as Algorae continues to build its pharmaceutical commercialisation platform and progress its AI drug discovery work.

View the announcement: https://t.co/HF6ZW7UzFa

#ASX #1AI #Pharmaceuticals #Healthcare #Biotech

[Investability @investability_]

#1AI webinar today

Join Investability Principal Dannika Warburton and @algoraepharma Executive Chairman David Hainsworth for a live investor update on supply agreements, TGA pathways and the ramp-up to first revenue in 2026.
11am AWST / 1pm AEST
Register: https://t.co/FW7SNzZQkL

[Algorae Pharmaceuticals @algoraepharma]

#1AI webinar reminder

Join Algorae Pharmaceuticals Executive Chairman David Hainsworth next Tuesday 28 April for an investor update covering the Company’s operations, priorities and Q2 2026 outlook.

A timely opportunity to hear directly from management on Algorae’s AI-enabled drug discovery and pharma commercialisation strategy.

11:00am AWST / 1:00pm AEST

🖋️ Register here: https://t.co/bgMAiD7Z75

#ASX #Biotech #HealthTech #InvestabilityIR

[Algorae Pharmaceuticals @algoraepharma]

Want the latest from Algorae Pharmaceuticals (ASX: #1AI)?

Tune in on Tuesday 28 April as Executive Chairman David Hainsworth shares an investor update on the Company’s operations, priorities and Q2 2026 outlook.

If Algorae’s AI-enabled approach to drug discovery and pharma commercialisation is on your watchlist, this is one to dial into.

11:00am AWST / 1:00pm AEST

🔔View announcement: https://t.co/stZqt2v7Pu
🖋️Register now: https://t.co/bgMAiD7Z75

#ASX @Investability_

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: 1AI) has completed a productive week in India, supporting the Company’s focus on commercial execution and partner engagement.

The visit provided valuable on-the-ground insight across manufacturing capability, supply chain readiness and strategic alignment as Algorae advances its capital-light pharmaceutical commercialisation model.

Initiatives like this help strengthen the foundations for disciplined execution and support Algorae’s broader pathway toward commercial growth.

Keep up to date for more: https://t.co/DYgOhcz2aN

#ASX #1AI #Algorae #Pharma #Commercialisation

[Algorae Pharmaceuticals @algoraepharma]

Algorae (ASX: #1AI) has strengthened its balance sheet with a $3.99M capital raise.

The funding supports growth across AlgoraeRx commercialisation and the AlgoraeOS R&D pipeline, with pro forma cash of ~$5.56M plus access to a $3.0M debt facility.

View the announcement: https://t.co/RHwqRojwYJ

[Algorae Pharmaceuticals @algoraepharma]

A key commercial milestone for Algorae (ASX: 1AI)

The Company has lodged its first TGA registration application, which has now passed preliminary assessment and moved to evaluation.

This is the first product from AlgoraeRx’s initial 7-product portfolio to enter the registration pathway - an important step toward potential commercial supply in Australia and New Zealand.

View the full announcement: https://t.co/CrrQ2vO8DI

#ASX #1AI #Biotech #Pharma

[Algorae Pharmaceuticals @algoraepharma]

Algorae (ASX: 1AI) is advancing validation of its AI-driven drug discovery platform, with a second screening program now underway with Peter MacCallum Cancer Centre.

program will assess 24 high-priority drug combination candidates across four cancer cell lines, with key preclinical data expected within six months.

This marks another important step in translating AlgoraeOS predictions into biological validation and supporting future development and commercial pathway discussions.

🔔View the full announcement: https://t.co/2la7d9MqBE

#1AI #ASXnews

[Algorae Pharmaceuticals @algoraepharma]

Algorae was pleased to spend time on the ground with Cadila Pharmaceuticals Limited this week as part of its broader India manufacturing program.

Engagements of this nature are important in informing execution planning, strengthening partner understanding and supporting the company’s commercial-readiness strategy.

#1AI #Algorae #Pharma #Manufacturing #Execution

[Algorae Pharmaceuticals @algoraepharma]

Algorae is in India this week as part of its ongoing work to support future commercial readiness.

The visit is focused on partner engagement, manufacturing capability assessment and progressing key execution workstreams that underpin the company’s broader commercial pathway.

Selected updates will be shared during the week where appropriate.

For more, https://t.co/DYgOhcz2aN

#1AI #Algorae #Pharma #Commercialisation #Execution

[Algorae Pharmaceuticals @algoraepharma]

Algorae is in India this week as part of its ongoing work to support future commercial readiness.

The visit is focused on partner engagement, manufacturing capability assessment and progressing key execution workstreams that underpin the company’s broader commercial pathway.

Selected updates will be shared during the week where appropriate.

For more, https://t.co/DYgOhcz2aN

#1AI #Algorae #Pharma #Commercialisation #Execution

[Algorae Pharmaceuticals @algoraepharma]

Algorae Pharmaceuticals (ASX: 1AI) was recently featured in @StockheadAU's Tony’s Takeaway, with Tony Locantro highlighting the Company’s AI-driven approach to identifying potential drug combinations and its commercial pathway through partnerships including Dr. Reddy’s.

With AI-enabled drug repurposing and licensing potential in focus, Algorae continues to build momentum around a differentiated biotech strategy at the intersection of healthcare and technology.

▶️Watch it here: https://t.co/V09ANmnJjf

#ASX #1AI #Biotech #AI #HealthcareInvesting #SmallCaps

[Algorae Pharmaceuticals @algoraepharma]

Algorae appoints senior pharma executive David Gulland as Non-Executive Director.

Former GM of HPS Pharmacies, with experience in pharmaceutical distribution and healthcare services as Algorae scales its commercial business.

Mr Gulland will also become COO of AlgoraeRx from 23 March.

🔔Read the full announcement: https://t.co/Aou5SqROfr

#Healthcare #Pharmaceuticals #ASX #Biotech